Worth reading
65In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
1.3
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFull year ended August 202612 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥17,205 million+1.3%
Operating profit¥3,625 million+1.2%
Ordinary income¥3,835 million+3.5%
Net income¥2,650 million+3.0%
Gross Profit Margin40 %
Operating profit margin21.1 %
Selling, general and administrative expenses¥3,262 million
Results for the three months of the current quarter
Fourth quarter of the fiscal year ended August 2026
Net Sales
39 Hundreds of millions of yen+8.8%
Full-year earnings forecast
Fiscal year ending August 2027
Net Sales
¥17,500 million
Gross profit
¥7,038 million
Selling, general and administrative expenses
¥3,436 million
Operating profit
¥3,602 million
Ordinary income
¥3,893 million
Net income
¥2,660 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing as plannedBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Gross profit
Fiscal year ending August 2026
Factors related to revenue¥88 million
Factors related to profit margins¥88 million
Outlook for the fiscal year ending August 2027
Factors related to revenue¥118 million
Factors related to profit margins¥33 million
Margin Factors
Cost exchange rate
Fiscal year ending August 2026¥7 million
Fiscal year ending August 2027¥-130 million
Overseas Production Ratio
Fiscal year ending August 2026¥90 million
Fiscal year ending August 2027¥90 million
Processing fees
Fiscal year ending August 2026¥-80 million
Fiscal year ending August 2027¥-130 million
Raw Materials
Fiscal year ending August 2026¥-170 million
Fiscal year ending August 2027¥-140 million
Overseas logistics costs
Fiscal year ending August 2026¥60 million
Fiscal year ending August 2027¥20 million
Price revisions and other factors
Fiscal year ending August 2026¥181 million
Fiscal year ending August 2027¥323 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Cost exchange rate
Fiscal year ending August 2027158.1 Yen/Dollar
Overseas Production Ratio
Fiscal year ending August 202761.5 %
Gross Profit Margin
Fiscal year ending August 202740.2 %
Foreign Exchange Assumptions for the fiscal year ending August 2029150 Yen/Dollar
New initiatives
- Introduction of the executive officer system from 1 September 2026
- Expansion of the miffy product lineup
- Expansion of overseas operations using the Seoul, South Korea branch
- System investments totaling ¥1.1 billion, including renewal of core systems
- Introduction of the latest cutting machine
Key KPIsA metric the company considers important as a management benchmark.
Core Market Sales Year on Year3.7
Peripheral Market Sales Year on Year-5.4
Overseas Market Sales Year on Year16.9
Overseas production ratio58.5
Equity ratio92.6
ROE6.6
Segment results
Core market
Net Sales¥12,437 million
Year on year against the same period last year+3.7%
Peripheral market
Net Sales¥4,506 million
Year on year against the same period last year-5.4%
Overseas markets
Net Sales¥261 million
Year on year against the same period last year+16.9%
Patient wear
Net Sales¥2,798 million
Year on year against the same period last year-11.8%
Surgical wear
Net Sales¥1,708 million
Year on year against the same period last year+7.3%
Medium-term management plan targets
Target fiscal yearFiscal year ending August 2029
Net Sales
185 Hundreds of millions of yen
Operating profit
40 Hundreds of millions of yen
Market Size / Share
Domestic Core Market ShareMore than 60%
Capital expenditures
¥310 million
Annual Dividend
¥70 per share
End of period70
Payout ratio
Standalone basis; basic policy50 %
Acquisition of treasury shares
Maximum number of shares to be acquired60 10,000 shares; ¥100 million
Maximum acquisition amount10 10,000 shares; ¥100 million
Period2 October–31 December 2026
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Full year ended August 2026 |
| Net Sales | ¥17,205 million (YoY +1.3%) |
| Operating profit | ¥3,625 million (YoY +1.2%) |
| Ordinary income | ¥3,835 million (YoY +3.5%) |
| Net income | ¥2,650 million (YoY +3.0%) |
| Gross Profit Margin | 40 % |
| Operating profit margin | 21.1 % |
| Selling, general and administrative expenses | ¥3,262 million |
| Results for the three months of the current quarter | Net Sales 39 Hundreds of millions of yen (YoY +8.8%) / Subject Fourth quarter of the fiscal year ended August 2026 |
| Full-year earnings forecast | Subject Fiscal year ending August 2027 / Net Sales ¥17,500 million / Gross profit ¥7,038 million / Selling, general and administrative expenses ¥3,436 million / Operating profit ¥3,602 million / Ordinary income ¥3,893 million / Net income ¥2,660 million |
| Self-assessment against the plan | Progressing as planned |
| Segment results | Core market Net Sales ¥12,437 million / yoy_pct ¥3.7 million / Peripheral market Net Sales ¥4,506 million / yoy_pct ¥-5.4 million / Overseas markets Net Sales ¥261 million / yoy_pct ¥16.9 million / Patient wear Net Sales ¥2,798 million / yoy_pct ¥-11.8 million / Surgical wear Net Sales ¥1,708 million / yoy_pct ¥7.3 million |
| Breakdown of Factors Affecting the Change | Gross profit Fiscal year ending August 2026 Factors related to revenue ¥88 million / Factors related to profit margins ¥88 million / Outlook for the fiscal year ending August 2027 Factors related to revenue ¥118 million / Factors related to profit margins ¥33 million / Margin Factors Cost exchange rate Fiscal year ending August 2026 ¥7 million / Fiscal year ending August 2027 ¥-130 million / Overseas Production Ratio Fiscal year ending August 2026 ¥90 million / Fiscal year ending August 2027 ¥90 million / Processing fees Fiscal year ending August 2026 ¥-80 million / Fiscal year ending August 2027 ¥-130 million / Raw Materials Fiscal year ending August 2026 ¥-170 million / Fiscal year ending August 2027 ¥-140 million / Overseas logistics costs Fiscal year ending August 2026 ¥60 million / Fiscal year ending August 2027 ¥20 million / Price revisions and other factors Fiscal year ending August 2026 ¥181 million / Fiscal year ending August 2027 ¥323 million |
| Key KPIs | Core Market Sales Year on Year 3.7 / Peripheral Market Sales Year on Year -5.4 / Overseas Market Sales Year on Year 16.9 / Overseas production ratio 58.5 / Equity ratio 92.6 / ROE 6.6 |
| Assumptions Underlying the Business Outlook | Cost exchange rate Fiscal year ending August 2027 158.1 Yen/Dollar / Overseas Production Ratio Fiscal year ending August 2027 61.5 % / Gross Profit Margin Fiscal year ending August 2027 40.2 % / Foreign Exchange Assumptions for the fiscal year ending August 2029 150 Yen/Dollar |
| Medium-term management plan targets | Target fiscal year Fiscal year ending August 2029 / Net Sales 185 Hundreds of millions of yen / Operating profit 40 Hundreds of millions of yen |
| Annual Dividend | ¥70 per share |
| Payout ratio | 50 % |
| Acquisition of treasury shares | Maximum number of shares to be acquired 60 10,000 shares; ¥100 million / Maximum acquisition amount 10 10,000 shares; ¥100 million / Period 2 October–31 December 2026 |
| Capital expenditures | ¥310 million |
| Market Size / Share | Domestic Core Market Share More than 60% |
| New initiatives | Introduction of the executive officer system from 1 September 2026, Expansion of the miffy product lineup, Expansion of overseas operations using the Seoul, South Korea branch, System investments totaling ¥1.1 billion, including renewal of core systems, Introduction of the latest cutting machine |
Items this document does not state (8)
Progress against full-year forecastUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookFinancial targetsOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended August 2026, results benefited from winning major projects in the core market, the new miffy product range, sales from timing-shifted projects in Taiwan and sales from the Seoul branch in overseas markets. Patient wear sales declined due to a reactionary decline following major projects in the previous fiscal year and customers holding back on purchases for replenishment. For the fiscal year ending August 2027, the company expects higher costs for raw materials, processing and foreign exchange, while targeting higher sales through the launch of miffy products, sales of high-value-added products and stronger initiatives in overseas markets.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.